Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study
Zev A. Wainberg(Los Angeles Medical Center), Peter C. Enzinger(Dana-Farber Cancer Institute), Yoon‐Koo Kang(University of Ulsan), Shukui Qin(Nanjing University of Chinese Medicine), Kensei Yamaguchi(The Cancer Institute Hospital), Inho Kim(The Catholic University of Korea Seoul St. Mary's Hospital), Anwaar Saeed(The University of Kansas Cancer Center), Sang Cheul Oh(Korea University Medical Center), Jin Li(Shanghai East Hospital), Hacı Mehmet Türk(Bezmiâlem Vakıf Üniversitesi), Alexandra Teixeira(Hospital da Senhora da Oliveira Guimarães), Christophe Borg(Centre Hospitalier Universitaire de Besançon), Erika Hitre(National Institute of Oncology), Adrian Udrea, Giovanni Gerardo Cardellino, Raquel Guardeño Sanchez(Catalan Institute for Water Research), Helen Collins(Five Prime Therapeutics (United States)), Siddhartha Mitra(Five Prime Therapeutics (United States)), Yingsi Yang(Five Prime Therapeutics (United States)), Daniel V.T. Catenacci(University of Chicago), Keun‐Wook Lee(Seoul National University Bundang Hospital)
Cited by 216
Abstract
Related Papers
No related papers found
Powered by citation graph analysis